Improving the outcome in treatment-resistant schizophrenia
![](https://ec.europa.eu/newsroom/repository/picture/2016-12/18_03_16_small_12586.jpg)
Related topics
Health Innovation Health, Demographic Change and Wellbeing Denmark Germany Netherlands United Kingdom Icelanddate: 18/03/2016
Project: Pharmacogenomic biomarkers as clinical d...
acronym: CRESTAR
See also: CORDIS
The Crestar project looked for genetic and clinical biomarkers that indicate whether a person suffering from schizophrenia is likely to respond to standard antipsychotic drugs or whether clozapine is likely to be required. Coordinated by King’s College London, it draws on thousands of DNA samples donated by patients and healthy individuals across Europe.